Our Story |
|
We develop cancer detection, imaging, and therapeutic drugs that we believe will treat many forms of cancer more effectively. We have a unique approach compared to current products and development. Our proprietary products and processes enable more effective identification, targeting, and treatment of cancer, regardless of location and type. Our technology gives us the ability to cost-effectively develop new, specific cancer therapies – essentially a platform giving us a competitive and sustainable advantage to develop better drugs more quickly and safely.
The Da Zen of opportunity is the result of two professors, who have spent their lifetime in cancer research (over 50 years each), want to bring their cumulative lifetime of research work to the world. Their technologies have been patented by their universities and results have been confirmed in other independent laboratories. The proprietary and successful research, now available for us to commercialize, was created using grant-funded research and development by our scientific team at various universities. Therefore, all of our company's funding up to now, over 10 years of work, has been with non-dilutive equity.
Since we have many years of research completed already, we will work with clinics and hospitals to begin human clinical trials:
1. By detecting the presence of cancer in a patient by assessing a serum marker.
2. By confirming the presence of tumors and metastases in patients using our imaging compound.
3. By performing an optional genetic test using tissues and cells from the patient. This test will enable us to see the patient’s uptake of our drug, through imaging, and, we believe, creates a better opportunity for successful treatment. This will also give us a comprehensive patient record.
4. We will proceed to treat the consented patients with our targeted agent.
Our targeted drug has unique properties to restore therapeutic resistant tumors to respond to existing therapies again. If the response is positive, we will look at the patient’s genetic profiling and will select the next patients, based on his/her responsiveness profiling and on genetic profiling, to select and treat our next patient. This will greatly increase the responsive rate of our patients. This will give us much more effective clinical trials, and, we believe, help us receive FDA approval more quickly.
We are fairly confident that our strategy could work in cancer patients because the drug we are using for the therapy has already been approved by the FDA. We are simply making it effective again. The problem with these drugs is their toxicity and tumor resistance. But, we have evidence that we have overcome these two problems.
1. The chemical structure of our carrier is a family of indocyanine green (ICG) that is approved by the FDA.
2. Our technology improves greatly the delivery of effective therapeutic drugs to the cancer cells directly.
a. The delivered drug accumulates in the patient’s tumors for a very long period of time (up to three weeks.)
b. We observed no toxicity of our drug to healthy tissues, and our drug appears to accumulate exclusively in tumors due to the specificity of our patented carrier.
We believe this is a paradigm shift for cancer detection and treatment. We are working with a GLP company and conducting clinical testing currently. We believe our FDA approval process can be fast-tracked because our initial targets are fast-growing cancers, such as pancreatic cancer and lung cancer, with no real effective therapeutic options.
Because of its light-emitting property, the imaging agent we developed has the potential to be used for robotic cancer surgery and potentially can visualize circulating tumor cells.
The Da Zen of opportunity is the result of two professors, who have spent their lifetime in cancer research (over 50 years each), want to bring their cumulative lifetime of research work to the world. Their technologies have been patented by their universities and results have been confirmed in other independent laboratories. The proprietary and successful research, now available for us to commercialize, was created using grant-funded research and development by our scientific team at various universities. Therefore, all of our company's funding up to now, over 10 years of work, has been with non-dilutive equity.
Since we have many years of research completed already, we will work with clinics and hospitals to begin human clinical trials:
1. By detecting the presence of cancer in a patient by assessing a serum marker.
2. By confirming the presence of tumors and metastases in patients using our imaging compound.
3. By performing an optional genetic test using tissues and cells from the patient. This test will enable us to see the patient’s uptake of our drug, through imaging, and, we believe, creates a better opportunity for successful treatment. This will also give us a comprehensive patient record.
4. We will proceed to treat the consented patients with our targeted agent.
Our targeted drug has unique properties to restore therapeutic resistant tumors to respond to existing therapies again. If the response is positive, we will look at the patient’s genetic profiling and will select the next patients, based on his/her responsiveness profiling and on genetic profiling, to select and treat our next patient. This will greatly increase the responsive rate of our patients. This will give us much more effective clinical trials, and, we believe, help us receive FDA approval more quickly.
We are fairly confident that our strategy could work in cancer patients because the drug we are using for the therapy has already been approved by the FDA. We are simply making it effective again. The problem with these drugs is their toxicity and tumor resistance. But, we have evidence that we have overcome these two problems.
1. The chemical structure of our carrier is a family of indocyanine green (ICG) that is approved by the FDA.
2. Our technology improves greatly the delivery of effective therapeutic drugs to the cancer cells directly.
a. The delivered drug accumulates in the patient’s tumors for a very long period of time (up to three weeks.)
b. We observed no toxicity of our drug to healthy tissues, and our drug appears to accumulate exclusively in tumors due to the specificity of our patented carrier.
We believe this is a paradigm shift for cancer detection and treatment. We are working with a GLP company and conducting clinical testing currently. We believe our FDA approval process can be fast-tracked because our initial targets are fast-growing cancers, such as pancreatic cancer and lung cancer, with no real effective therapeutic options.
Because of its light-emitting property, the imaging agent we developed has the potential to be used for robotic cancer surgery and potentially can visualize circulating tumor cells.
